

RealRate

PHARMACEUTICAL 2018











RealRate

PHARMACEUTICAL 2018

XBiotech Inc. Rank 47 of 342



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 94% points. The greatest weakness of XBiotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 213%, being 167% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	33,332
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,792
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-825
Other Expenses	0
Other Liabilities	18
Other Net Income	909
Other Revenues	0
Property and Equipment	29,640
Research and Development	26,424
Selling, General and Administrative Expense	7,635

Output Variable	Value in 1000 USD
Assets	62,972
Liabilities	2,810
Expenses	34,059
Revenues	0
Stockholders Equity	60,162
Net Income	-33,150
Comprehensive Net Income	-33,562
Economic Capital Ratio	213%

